Bank says Demant prognosis probably affected by component shortages

Uncertainties about the lack of components and transportation as well as increased investments are contributing factors dampening the profit outlook for Demant’s 2022, says analyst at Danish bank Sydbank.

Photo: Demant / PR

Demant has released its expectations for 2022, including an organic growth of 5–9 percent and an EBIT result of DKK 3.4–3.7bn (USD 521–567m), in connection with the full-year financial figures for 2021 on Tuesday.

While the growth calculation hit the bullseye of analysts’ estimation, their expected EBIT result is a lot higher than even the midpoint of Demant’s interval.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs